The organization of the REPRIEVE (A5332) trial and inter-relationships between the NHLBI, the Clinical Coordinating Center (CCC), the Data Coordinating Center (DCC), the various committees, and the potential sites are outlined in the organization chart. Furthermore, REPRIEVE is based on the collaboration, under NHLBI direction, of critical NIAID funded HIV clinical research networks and sites, as well as with Kowa pharmaceuticals to provide study drug and placebo. The CCC and DCC PIs will form the Executive Committee (EC) with representatives of the NHLBI and DAIDS. The Operational Leadership Committee will include the EC members plus Co-Investigators Carl Fichtenbaum, M.D., Carlos Malvestutto, M.D., M.P.H., Judy Aberg, M.D., Markella Zanni, M.D.